Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avanir Pharmaceuticals and Concert Pharmaceuticals have signed a license agreement to develop and commercialize deuterium-modified dextromethorphan for disorders of the nervous system.
Subscribe to our email newsletter
As per the agreement, Concert will receive an upfront payment and upon achievement of certain predefined clinical, regulatory and commercial targets, it is eligible to receive additional milestone payments.
Additional Concert will receive tiered royalties on worldwide sales of products containing d-DM.
Avanir is responsible for research, development and commercialization of d-DM and Concert will provide manufacturing support for investigational new drug enabling studies.
The agreement includes the rights to multiple deuterium-modified dextromethorphan compounds.
Avanir chief business officer and corporate development senior vice president Greg Flesher said the company intends to explore the utility of d-DM in neurological and psychiatric disorders.